GLOBAL FACTOR VIII DEFICIENCY TREATMENT MARKET ANALYSIS

Global factor VIII deficiency treatment Market, By Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), Desmopressin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Apr 2023
Code : CMI3257
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Factor VIII Deficiency Treatment Market: Key Developments

In November 2022, the U.S. Food and Drug Administration announced that they have approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia A and B (congenital Factor IX and/or VIII deficiency)

In December 2021, Pfizer Inc., a U.S.-based multinational biopharmaceutical company, and Sangamo Therapeutics, Inc., a genomic medicines company, announced that their drug candidate giroctocogene fitelparvovec an investigational gene therapy for patients with moderately severe to severe hemophilia A, meet the regulatory requirements.

Global Factor VIII Deficiency Treatment Market: Key Players

Major players operating in the Global Factor VIII Deficiency Treatment market include Baxter, Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S